00:00Pharmaceuticals, until now available, have always obtained results that are both modest and transient,
00:15and therefore have never been able to modify the outcome, the evolution of these subjects,
00:23which is systematically unfavorable both on the level of persistence and crisis,
00:28as we have said, of all the associated handicaps.
00:33Today we have this new drug at our disposal, which has shown significant effectiveness
00:43both in controlled trials, in the short term,
00:47and in in-open real-world treatments that have also been carried out for years.
00:57And we can say that at least 50% of the patients who have taken this drug
01:05have had an extremely significant benefit.
01:10A benefit both on the level of crisis control and on the level of quality of life,
01:20partly because obviously, when there are no more crises, there is an improvement in quality of life,
01:30but also for a direct effect of phenfluramine on the cognitive skills of the behavioral language,
01:41on the quality of sleep.
01:44This is probably due to the fact that phenfluramine does not have a single mechanism of action,
01:52but has multiple mechanisms of action, and therefore is able to obtain results,
01:59even though it is a form that can be due to very different causes.
02:08So it acts on the mechanism of unbalancing that supports crises,
02:14regardless of the cause that has caused them,
02:18rebalancing the unbalancing that produces crises,
02:25through the mechanisms of action, in particular on the receptors of serotonin
02:32and on the receptors of sigma-1, which are significantly involved in the genesis,
02:40in the determination of many forms of epilepsy.
Comments